Quinine (hydrochloride)
Based on 7 publication(s) in Google Scholar
Quinine hydrochloride is an alkaloid extracted from cinchona bark and exhibits oral activity, acting as a potassium channel inhibitor. Quinine hydrochloride modulates the tolerance of red blood cells and presents dose-dependent toxicity and embryonic effects. Quinine hydrochloride is a typical hemolysin that directly lyses red blood cells, with cellular components of red blood cell membranes as its action targets. Quinine hydrochloride disrupts red blood cell membranes and induces hemolysis at high concentrations, while merely weakening the anti-hemolytic capacity of red blood cells at low concentrations. Quinine hydrochloride continuously reduces red blood cell tolerance after in vivo administration, and high doses can also alter blood cell counts. Quinine hydrochloride can be applied to researches related to red blood cell hemolysis, cancer and malaria.
For research use only. We do not sell to patients.
- Purity: 99.83%
- CAS No.: 130-89-2
- Formula: C20H25ClN2O2
- Molecular Weight:360.88
-
Storage:
RT, stored under nitrogen.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Antiparasitic Compound library
HY-L082
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Food Additive Library
HY-L093
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Potassium Channel Compound Library
HY-L119
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Quinine (hydrochloride)
More- Neurosci Bull. 2025 May 6. [Abstract]
- Cell Mol Life Sci. 2025 Nov 25;82(1):419. [Abstract]
- J Mol Cell Biol. 2025 Jan 23:mjae051. [Abstract]
- ACS Omega. 2024 Feb 28;9(10):11870-11882. [Abstract]
- Mol Med Rep. 2021 May;23(5):313. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Norwegian University of Science and Technology. 2019 Sep.
All Parasite Isoforms
More
Biological Activity
Quinine hydrochloride acts as a simple hemolysin on rabbit erythrocytes; pretreatment of rabbit erythrocytes reduces their resistance to the lytic effects of saponin and sodium taurocholate in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Quinine hydrochloride (administered orally daily at doses of 1-200 mg/kg for 13 consecutive weeks) causes dose-dependent decreases in body weight and food intake, as well as reversible biochemical changes[3].
Quinine hydrochloride (60-120 mg/kg per day; p.o.; daily administration; for 13 consecutive weeks) causes reversible inhibition of body weight gain, reduced food intake, and transient increases in kidney weight in male rats at doses ≥85 mg/kg per day[3].
Quinine hydrochloride (85-200 mg/kg per day; p.o.; daily administration; for 13 consecutive weeks) does not induce ototoxic effects or hearing impairment[3].
Quinine hydrochloride (50-200 mg/kg per day; p.o.; daily administration; gestational days 6-15) is orally administered to mated Sprague-Dawley rats on gestational days 6-15. Maternal toxicity occurs at doses ≥100 mg/kg, while mild fetal effects (decreased body weight, increased incidence of malformations) are observed at a dose of 200 mg/kg[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male and female)[3]
-
Dosage:25 mg/kg per day; 100 mg/kg per day; 200 mg/kg per day; 250 mg/kg per day
-
Administration:p.o.; daily; 4 weeks
-
Result:Decreased food intake and body weight at 100, 200 and 250 mg/kg daily.
Slightly impaired food utilization at the end of the study.
Suppressed weight gain in females at 25 mg/kg daily.
Elevated spleen weight in all treated male rats.
Lowered kidney and adrenal weights in all treated female rats.
-
Animal Model:Sprague-Dawley (male and female)[3]
-
Dosage:1 mg/kg per day; 10 mg/kg per day; 40 mg/kg per day; 100 mg/kg per day; 200 mg/kg per day
-
Administration:p.o.; daily; 13 weeks
-
Result:Retarded body weight gain at 100 and 200 mg/kg daily.
Decreased food intake and utilization at 200 mg/kg daily.
Accelerated weight gain in the 200 mg/kg group during recovery.
Raised plasma urea across genders at 100 and 200 mg/kg daily.
Elevated serum inorganic phosphorus in females at 40, 100 and 200 mg/kg daily.
Lowered total protein in females at 100 and 200 mg/kg daily.
Reversed all biochemical alterations in the recovery period.
Aggravated periportal glycogen depletion in females at 100 and 200 mg/kg daily.
Produced no changes in organ weight, vision or hearing function.
-
Animal Model:Sprague-Dawley (male and female)[3]
-
Dosage:60 mg/kg per day; 85 mg/kg per day; 120 mg/kg per day
-
Administration:p.o.; daily; 13 weeks
-
Result:Recorded no drug-related deaths.
Induced mild alopecia since week 3 at 120 mg/kg daily.
Retarded weight gain and food intake at 85/120 mg/kg daily, reversible during recovery.
Elevated phosphorus in females at 120 mg/kg daily, with partial persistence.
Increased kidney weight in males at 85/120 mg/kg daily, which recovered later.
Caused no abnormalities in blood, urine, ophthalmic and histological examinations.
-
Animal Model:Sprague-Dawley (time-mated female)[3]
-
Dosage:50 mg/kg per day; 100 mg/kg per day; 200 mg/kg per day
-
Administration:p.o.; daily; gestation days 6-15
-
Result:Induced salivation, partial alopecia, excessive water intake and mild growth retardation in maternal rats at 100 and 200 mg/kg daily.
Exerted no impacts on litter size, embryo survival and foetal malformation rate across all doses.
Remarkably lowered average foetal weight at the 200 mg/kg daily dose.
Elevated the rates of visceral anomalies, skeletal anomalies and sternebrae variations in foetuses at 200 mg/kg daily.
Chemical Information
-
CAS No. 130-89-2
-
Appearance Solid
-
Molecular Weight 360.88
-
Formula C20H25ClN2O2
-
Color White to off-white
-
SMILES
O[C@H](C1=CC=NC2=C1C=C(OC)C=C2)[C@@]3([H])[N@](C[C@@H]4C=C)CC[C@H]4C3.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
RT, stored under nitrogen
In solvent -80°C 1 year -20°C 6 months
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Neurosci Bull
A Novel Functional Method of Protector Screening for Zebrafish Lateral Line Hair Cells via the Acoustic Escape Response. [Abstract]2025 May 6. PMID: 40329138 -
Cell Mol Life Sci
2025 Nov 25;82(1):419. PMID: 41288707 -
J Mol Cell Biol
2025 Jan 23:mjae051. PMID: 39848918 -
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
Mol Med Rep
2021 May;23(5):313. PMID: 34240224 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Solvent & Solubility
DMSO : 100 mg/mL (277.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7710 mL | 13.8550 mL | 27.7100 mL | 69.2751 mL |
| 5 mM | 0.5542 mL | 2.7710 mL | 5.5420 mL | 13.8550 mL | |
| 10 mM | 0.2771 mL | 1.3855 mL | 2.7710 mL | 6.9275 mL | |
| 15 mM | 0.1847 mL | 0.9237 mL | 1.8473 mL | 4.6183 mL | |
| 20 mM | 0.1386 mL | 0.6928 mL | 1.3855 mL | 3.4638 mL | |
| 25 mM | 0.1108 mL | 0.5542 mL | 1.1084 mL | 2.7710 mL | |
| 30 mM | 0.0924 mL | 0.4618 mL | 0.9237 mL | 2.3092 mL | |
| 40 mM | 0.0693 mL | 0.3464 mL | 0.6928 mL | 1.7319 mL | |
| 50 mM | 0.0554 mL | 0.2771 mL | 0.5542 mL | 1.3855 mL | |
| 60 mM | 0.0462 mL | 0.2309 mL | 0.4618 mL | 1.1546 mL | |
| 80 mM | 0.0346 mL | 0.1732 mL | 0.3464 mL | 0.8659 mL | |
| 100 mM | 0.0277 mL | 0.1386 mL | 0.2771 mL | 0.6928 mL |
Quinine (hydrochloride) Related Classifications
HY-110082 Related Classifications
Powered by Bioz